← All stories
Markets
Could Solvonis (LSE:SVNS) Patent Drive FTSE 100 Biotech Focus?
Highlights Solvonis Therapeutics has secured European patent allowance for its lead PTSD drug candidate, SVN-114. The patent covers the underlying chemical compound and strengthens protection around the programme. Further pharmacology, safe…
Covered by 1 outlet
All coverage · 1 article